S3-Leitlinie Prostatakarzinom - AWMF

9. Literatur
Brachytherapy-and-Proton-Beam-Therapy-for-Treatment-of-Clinically-Localized-Low-Risk-
Prostate-Cancer.html
182. Nihei K, Ogino T, Onozawa M, Murayama S, Fuji H, Murakami M, Hishikawa Y. Multi-
Institutional Phase II Study of Proton Beam Therapy for Organ-Confined Prostate Cancer
Focusing on the Incidence of Late Rectal Toxicities. Int J Radiat Oncol Biol Phys 2010.
http://www.ncbi.nlm.nih.gov/pubmed/20832180
183. Terasawa T, Dvorak T, Ip S, Raman G, Lau J, Trikalinos TA. Systematic review: chargedparticle
radiation therapy for cancer. Ann Intern Med 2009;151(8):556-65.
http://www.ncbi.nlm.nih.gov/pubmed/19755348
184. Mendenhall NP, Li Z, Hoppe BS, Marcus RB, Jr., Mendenhall WM, Nichols RC, Morris CG,
Williams CR, Costa J, Henderson R. Early Outcomes from Three Prospective Trials of Imageguided
Proton Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2010.
http://www.ncbi.nlm.nih.gov/pubmed/21093164
185. Brada M, Pijls-Johannesma M, De RD. Current clinical evidence for proton therapy. Cancer J
2009;15(4):319-24. http://www.ncbi.nlm.nih.gov/pubmed/19672149
186. Beyer DC, Brachman DG. Failure free survival following brachytherapy alone for prostate
cancer: comparison with external beam radiotherapy. Radiother Oncol 2000;57(3):263-7.
http://www.ncbi.nlm.nih.gov/pubmed/11104883
187. D'Amico AV, Tempany CM, Schultz D, Cormack RA, Hurwitz M, Beard C, Albert M, Kooy H,
Jolesz F, Richie JP. Comparing PSA outcome after radical prostatectomy or magnetic
resonance imaging-guided partial prostatic irradiation in select patients with clinically
localized adenocarcinoma of the prostate. Urology 2003;62(6):1063-7.
http://www.ncbi.nlm.nih.gov/pubmed/14665356
188. Sharkey J, Cantor A, Solc Z, Huff W, Chovnick SD, Behar RJ, Perez R, Otheguy J, Rabinowitz
R. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized
prostate cancer: a 12-year experience from a single group practice. Brachytherapy
2005;4(1):34-44. http://www.ncbi.nlm.nih.gov/pubmed/15737905
189. Zelefsky MJ, Wallner KE, Ling CC, Raben A, Hollister T, Wolfe T, Grann A, Gaudin P, Fuks Z,
Leibel SA. Comparison of the 5-year outcome and morbidity of three-dimensional conformal
radiotherapy versus transperineal permanent iodine-125 implantation for early-stage
prostatic cancer. J Clin Oncol 1999;17(2):517-22.
http://www.ncbi.nlm.nih.gov/pubmed/10080594
190. Koukourakis G, Kelekis N, Armonis V, Kouloulias V. Brachytherapy for prostate cancer: a
systematic review. Adv Urol 2009;327945.
http://www.ncbi.nlm.nih.gov/pubmed/19730753
191. Ash D, Flynn A, Battermann J, de RT, Lavagnini P, Blank L. ESTRO/EAU/EORTC
recommendations on permanent seed implantation for localized prostate cancer. Radiother
Oncol 2000;57(3):315-21. http://www.ncbi.nlm.nih.gov/pubmed/11104892
192. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS)
recommendations for transperineal permanent brachytherapy of prostate cancer. Int J
Radiat Oncol Biol Phys 1999;44(4):789-99.
http://www.ncbi.nlm.nih.gov/pubmed/10386635
193. Potters L, Morgenstern C, Calugaru E, Fearn P, Jassal A, Presser J, Mullen E. 12-year
outcomes following permanent prostate brachytherapy in patients with clinically localized
prostate cancer. J Urol 2005;173(5):1562-6.
http://www.ncbi.nlm.nih.gov/pubmed/15821486
© Leitlinienprogramm Onkologie | S3-Leitlinie Prostatakarzinom | Version 2.0, 1. Aktualisierung 2011